MedPath

InnoMedica Schweiz AG

InnoMedica Schweiz AG logo
🇨🇭Switzerland
Ownership
Subsidiary
Established
1988-01-01
Employees
1
Market Cap
-
Website
http://www.ipag.ch

Clinical Trials

2

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

Phase 2
Not yet recruiting
Conditions
Parkinson Disease
Interventions
Drug: Placebo
First Posted Date
2024-05-29
Last Posted Date
2024-05-29
Lead Sponsor
InnoMedica Schweiz AG
Target Recruit Count
40
Registration Number
NCT06431971
Locations
🇨🇭

Neurologisches Institut Konolfingen, Konolfingen, Switzerland

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

Phase 1
Active, not recruiting
Conditions
Parkinson Disease
Interventions
First Posted Date
2021-07-26
Last Posted Date
2024-03-15
Lead Sponsor
InnoMedica Schweiz AG
Target Recruit Count
22
Registration Number
NCT04976127
Locations
🇨🇭

Neurologisches Institut Konolfingen, Konolfingen, Bern, Switzerland

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.